Skip to main content

Table 1 Descriptive characteristics of Aboriginal people in Western Australia enrolled before and after PCV13 introduction (1 July 2011), by age group (August 2008–November 2014)

From: Predictors of pneumococcal carriage and the effect of the 13-valent pneumococcal conjugate vaccination in the Western Australian Aboriginal population

 

n (%)

 

<5 years

5–14 years

≥15 years

 

pre-PCV13

post-PCV13

pre-PCV13

post-PCV13

pre-PCV13

post-PCV13

Total

S. pneumoniae carriage

 Any serotype

406 (72.2)

334 (66.8)

235 (49.4)

251 (53.2)

90 (19.5)

41 (9.9)**

1357 (47.0)

  PCV7 serotype

59 (10.5)

32 (6.4)*

35 (7.4)

28 (5.9)

9 (1.9)

5 (1.2)

168 (5.8)

  PCV13-nonPCV7 serotype

76 (13.5)

29 (5.8)**

40 (8.4)

29 (6.1)

10 (2.2)

4 (1.0)

188 (6.5)

  PCV13 serotype

133 (23.7)a

60 (12.0)b**

74 (15.5)b

57 (12.1)

19 (4.1)

9 (2.2)

352 (12.2)

 Male

307 (54.6)

252 (50.6)

249 (52.3)

223 (47.2)

117 (25.3)

74 (17.9)

1222 (42.4)

 Respiratory symptoms

65 (13.6)

66 (13.2)

14 (3.0)

20 (4.2)

26 (5.7)

44 (10.7)

235 (8.4)

 Nasal discharge

294 (60.2)

234 (46.8)**

170 (36.2)

111 (23.5)**

31 (6.8)

43 (10.4)

883 (31.5)

 Remoteness index

  Metropolitan

68 (12.1)

71 (14.2)

62 (13.0)

76 (16.1)

26 (5.6)

63 (15.3)

366 (12.7)

  Regional

43 (7.7)

73 (14.6)

20 (4.2)

40 (8.5)

29 (6.3)

57 (13.8)

262 (9.1)

  Remote

451 (80.2)

356 (71.2)

394 (82.8)

356 (75.4)

407 (88.1)

293 (70.9)

2257 (78.2)

 ≥5 people sharing (crowding)

308 (65.7)

280 (57.1)**

291 (66.1)

294 (66.4)

282 (66.4)

194 (47.8)**

1649 (61.7)

 Sharing with ≥1 child <5 years

368 (78.6)

326 (66.5)**

336 (76.4)

303 (69.0)*

353 (83.6)

272 (67.3)**

1958 (73.5)

 Antibiotic use in previous 2 weeks

46 (8.5)

60 (12.3)

13 (2.7)

35 (7.7)**

23 (5.0)

39 (9.5)*

216 (7.6)

 Indoor environmental tobacco smoke exposure

103 (22.0)

103 (21.2)

91 (20.6)

96 (21.7)

131 (29.6)

91 (22.5)*

615 (22.9)

 Any environmental tobacco smoke exposure

325 (67.6)

340 (69.7)

272 (59.4)

287 (64.3)

297 (66.6)

260 (63.9)

1781 (65.3)

 Smoker

N/A

N/A

N/A

N/A

237 (59.1)

182 (52.1)

419 (55.6)

 Season

  Summer

43 (7.7)

23 (4.6)

51 (10.7)

20 (4.2)

18 (3.9)

22 (5.3)

177 (6.1)

  Autumn

108 (19.2)

94 (18.8)

103 (21.6)

82 (17.4)

91 (19.7)

93 (22.5)

571 (19.8)

  Winter

275 (48.9)

242 (48.4)

204 (42.9)

183 (38.8)

169 (36.6)

190 (46.0)

1263 (43.8)

  Spring

136 (24.2)

141 (28.2)

118 (24.8)

187 (39.6)

184 (39.8)

108 (26.2)

874 (30.3)

 PCV7 vaccinated

360 (88.9)

144 (90.6)

168 (69.4)

134 (82.2)

N/A

N/A

806 (83.2)

 PCV13 vaccinatedc

N/A

37 (59.7)

N/A

N/A

N/A

N/A

37 (26.2)

 Vaccination status unknown

151 (26.8)

283 (56.6)

165 (34.7)

295 (62.5)

N/A

N/A

894 (44.5)

H. influenzae

355 (63.2)

274 (54.8)**

170 (35.7)

186 (39.4)

40 (8.7)

24 (5.8)

1049 (36.4)

M. catarrhalis

353 (62.8)

356 (71.2)**

193 (40.5)

175 (37.1)

60 (13.0)

30 (7.3)**

1167 (40.5)

S. aureus

64 (11.4)

30 (6.0)**

73 (15.3)

77 (16.3)

46 (10.0)

35 (8.5)

325 (11.3)

  1. Denominators for proportions varied due to missing data. Proportions were compared using χ2
  2. *p < 0.05, **p < 0.01
  3. aTwo participants carried a PCV7 and PCV13-non-PCV7 serotype simultaneously
  4. bOne participant carried a PCV7 and PCV13-non-PCV7 serotype simultaneously
  5. cDenominator is number of participants at time of enrolment pre/post PCV13. Includes participants vaccinated with PCV7 prior to introduction of PCV13